Hormone replacement therapy and its association with LATE‐NC in older adults

by Clinical Neuropsychologist Online | Friday, August 7, 2026 | Dementia

Abstract INTRODUCTION Limbic-predominant age-related transactive response DNA-binding protein 43 (TDP-43) encephalopathy neuropathological change (LATE-NC) is a cause of dementia resembling Alzheimer’s disease (AD). The 90+ Study found women using hormone...

Plasma P‐tau217 for detecting amyloid clearance after donanemab in Alzheimer’s disease

by Clinical Neuropsychologist Online | Friday, August 7, 2026 | Dementia

Abstract INTRODUCTION This analysis of the phase 3 TRAILBLAZER-ALZ 2 trial examined whether plasma tau protein phosphorylated at threonine 217 (p-tau217) level can reliably monitor treatment-related amyloid clearance (TRAC) after donanemab treatment in early...

Dorsal raphe tau pathology disrupts sleep‐wake orchestration and sleep architecture in a sex‐specific manner

by Clinical Neuropsychologist Online | Friday, August 7, 2026 | Dementia

Abstract INTRODUCTION Sleep disturbances are frequent symptoms of Alzheimer’s disease (AD), mirrored by early pathology in the dorsal raphe nucleus (DRN). Whether early DRN pathology can drive sleep disturbances, and the relative contributions of serotonin...

A randomized phase 1b/2 trial of ABBV‐916 in adults with early Alzheimer’s disease

by Clinical Neuropsychologist Online | Friday, August 7, 2026 | Dementia

Abstract INTRODUCTION ABBV-916, an anti-amyloid immunotherapy, was evaluated in patients with early Alzheimer’s disease (AD). METHODS This phase 1b/2, double-blind, placebo-controlled study consisted of two stages: multiple ascending dose (Stage A) and dose...

Mapping PPA Care: Results of a Survey Study on Speech and Language Therapy for People With Primary Progressive Aphasia Across Germany

by Clinical Neuropsychologist Online | Thursday, August 6, 2026 | Dementia

Dementia, Ahead of Print. Background:Primary Progressive Aphasia (PPA) is a rare condition characterised by a gradual loss of language due to neurodegenerative processes including frontotemporal lobar degeneration and Alzheimer’s disease. Speech and language therapy...

Lecanemab use in Chinese patients with Alzheimer’s disease: a 12‐month multicenter real‐world study

by Clinical Neuropsychologist Online | Thursday, August 6, 2026 | Dementia

Abstract INTRODUCTION We evaluated lecanemab’s safety and cognitive outcomes in Chinese patients with Alzheimer’s disease (AD) and the utility of blood-based biomarkers (BBMs) for treatment guidance. METHODS A multicenter, real-world cohort enrolled 1042...